PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
An 80-Year-Old Man With Memory Loss
JAMA 283:1046-1053, Larson,E.B., 2000
Apolipoprotein E Genotyping in Alzheimer's Disease
Lancet 347:1091-1095, Tanzi,R.,et al, 1996
Apolipoprotein E Genotyping in the Diagnosis of Alzheimer's Disease:A Cautionary View
Ann Neurol 38:2-4, Bird,T.D., 1995
Statement of Use of Apolipoprotein E Testing for Alzheimer Disease
JAMA 274:1627-1629, Farrer,L.A.,et al, 1995
A Low, "Normal"Score on the Mini-Mental State Exam Predicts Development of Dementia after Three Years
JAGS 43:656-661, Braekhus,A.,et al, 1995
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
A 10-Item Smell Identification Scale Related to Risk for Alzheimers Disease
Ann Neurol 58:155-160, Taberr,M.H.,et al, 2005
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Early Alzheimer's Disease
NEJM 349:1056-1063, Kawas,C.H., 2003
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Potentially Reversible Conditions in 1000 Consecutive Memory Clinic Patients
JNNP 73:390-394, Hejl,A.,et al, 2002
Evaluation of CSf-tau and CSF-AB42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Arch Neurol 58:373-379,349, Andreasen,N.,et al, 2001
Altered Brain Activation in Cognitively Intact Individuals at High Risk for Alzheimer's Disease
Neurol 53:1391-1396, Smith,C.D.,et al, 1999
Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
NEJM 338:506-511, Mayeux,R.,et al, 1998
A Clinical Role for 99mTC-HMPAO SPECT in the Investigation of Dementia
JNNP 64:306-313, Talbot,P.R.,et al, 1998
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Frontotemporal Dementia and Early Alzheimer Disease:Differentiation with Frontal Lobe H-1 MR Spectroscopy
Radiology 203:829-836, Ernst,T.,et al, 1997
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the e4Allele for Apolipoprotein E
NEJM 334:752-758, 7911996., Reiman,E.M.,et al, 1996
Genetic Factors in Alzheimer's Disease:A Review of Recent Advances
Ann Neurol 40:829-840, Levy-Lahad,E.&Bird,T.D., 1996
Apolipoprotein E Genotyping in the Differential Diagnosis, Not Prediction, of Alzheimer's Disease
Ann Neurol 38:6-14, Roses,A.D., 1995
Electroencephalography as an Aid in the Exclusion of Alzheimer's Disease
Arch Neurol 51:280-284, Robinson,D.J.,et al, 1994
Diagnostic Value of SPECT with Tc 99m HMPAO in Alzheimer's Disease:A Population-Based Study
Neurol 44:454-461, Claus,J.J.,et al, 1994
Management of Neurological Disorders:Dementia
JNNP 57:1451-1456, Rossor,M.N., 1994
Alzheimer's Disease
BMJ 307:779-782, Rossor,M., 1993
Single-Photon Emission Computed Tomography (SPECT)
JAMA 263:561-564, Holman,B.L.&Tumeh,S.S., 1990
Iofetamine I 123 Single Photon Emission Computed Tomography is Accurate in Diagnosis of Alzheimer's Disease
Arch Int Med 150:752-756, Johnson,K.A.,et al, 1990
Reliability of Clinical Criteria for the Diagnosis of Dementia, A Longitudinal Multicenter Study
Arch Neurol 46:646-648, Forette,F.,et al, 1989
Diagnosing Dementia:Do We Get It Right?
BMJ 297:894-896, Homer,A.C.,et al, 1988